In order to prevent spam,
this email address cannot be copied.
Schizophrenia Research Forum: Researcher Profile - Chris Carter
Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Profile Membership/Get Newsletter Log In Contact Us
 For Patients & Families
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
Research News
Conference News
Plain English
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
What We Know
Animal Models
Drugs in Trials
Research Tools
Community Calendar
General Information
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by the Brain and Behavior Research Foundation and was created with funding from the U.S. National Institute of Mental Health.
Researcher Profile - Chris Carter

First Name:Chris
Last Name:Carter
Advanced Degrees:B.Sc, M.Sc, Ph.D
Street Address 1:Flat 2
Street Address 2:40 Baldslow Rd
State/Province:East Sussex
Zip/Postal Code:TN34 2EY
Country/Territory:United Kingdom
Email Address: 
(view policy) 
Member reports no financial or other potential conflicts of interest. [Last Modified: 2 November 2012]
View all comments by Chris Carter
Clinical Interests:
Depression, Bipolar disorder , Schizophrenia, Attention-deficit hyperactivity disorder (ADHD, ADD) , Autism spectrum disorders (pervasive developmental disorders)
Research Focus:
Immunology, Bioinformatics/Statistics, Signal transduction, Epidemiology, Neurotransmission, Pharmacology, Glia/myelin, Genetics, Glutamatergic transmission, Neuroanatomy/Systems Neuroscience
Work Sector(s):
Seeking work
Web Sites:
Reasearcher Bio
B.Sc Zoology (Leeds University)

M.Sc with Brenda Costall and Robert Naylor at Bradford University.

Ph.D with Chris Pycock At Bristol University. Dopamine in the frontal cortex and dopamine/serotonin interactions

Postdoc at David Marsden's Neurology department at the Institute of Psychiatry.
Gluatamate pathways and post-mortem studies in Huntington's disease.

Pharmaceutical: Synthelabo/Sanofi-Synthelabo (until 2005)
NMDA antagonists (Ifenprodil)/polyamines
Free radical scavengers
Neuroleptics (Amisulpiride)
Cytotoxic mechanisms in ischaemia
Head of Neuroscience Genomics unit.

Currently: Trawling genes and risk factors.

Top Papers
Carter C.J. The Fox and the Rabbits—Environmental Variables and Population Genetics (1) Replication Problems in Association Studies and the Untapped Power of GWAS (2) Vitamin A Deficiency, Herpes Simplex Reactivation and Other Causes of Alzheimer's Disease ISRN Neurology 2011

Carter C.J. Schizophrenia: A Pathogenetic Autoimmune Disease Caused by Viruses and Pathogens and Dependent on Genes> J Pathogens, 2011

Carter, C.J. Alzheimer's Disease: A Pathogenetic Autoimmune Disorder Caused by Herpes Simplex in a Gene-Dependent Manner Int.J.Alz.Dis. 2010

Carter CJ. Epstein-Barr and other viral mimicry of autoantigens, myelin and
vitamin D-related proteins and of EIF2B, the cause of vanishing white matter
disease: massive mimicry of multiple sclerosis relevant proteins by the
Synechococcus phage. Immunopharmacol Immunotoxicol. 2011 Apr 12. [Epub ahead of
print] PubMed PMID: 21486137.

Carter, C.J. Schizophrenia susceptibility genes directly implicated in the life cycles of
pathogens: cytomegalovirus, influenza, herpes simplex, rubella, and Toxoplasma
gondii. Schizophr Bull. 2009 Nov;35(6):1163-82. PMID: 18552348

Carter, C.J.
eIF2B and oligodendrocyte survival: where nature and nurture meet in bipolar disorder and schizophrenia? Schizophr Bull. 2007 Nov;33(6):1343-53 PMID: 17329232

Carter, C.J.Schizophrenia susceptibility genes converge on interlinked pathways related to glutamatergic transmission and long-term potentiation, oxidative stress and oligodendrocyte viability.
Schizophr Res. 2006 Sep;86(1-3):1-14 [Epub ahead of print] PMID: 16842972

Pycock CJ, Kerwin RW, Carter CJ. Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats. Nature. 1980 Jul 3;286(5768):74-6. PMID: 7393327

Carter CJ, Pycock CJ. Behavioural and biochemical effects of dopamine and noradrenaline depletion within the medial prefrontal cortex of the rat.
Brain Res. 1980 Jun 16;192(1):163-76. PMID: 7189685

properties. J Pharmacol Exp Ther. 1988 Dec;247(3):1222-32. PMID: 2849669

Gotti B, Duverger D, Bertin J, Carter C, Dupont R, Frost J, Gaudilliere B, MacKenzie ET, Rousseau J, Scatton B, et al. Ifenprodil and SL 82.0715 as cerebral anti-ischemic agents. I. Evidence for efficacy in models of focal cerebral ischemia. J Pharmacol Exp Ther. 1988 Dec;247(3):1211-21.

Nankai M, Fage D, Carter C. Striatal NMDA receptor subtypes: the pharmacology of N-methyl-D-aspartate-evoked dopamine, gamma-aminobutyric acid, acetylcholine and spermidine release. Eur J Pharmacol. 1995 Nov 3;286(1):61-70. PMID: 8566152

Aubin N, Curet O, Deffois A, Carter C. Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice. J Neurochem. 1998 Oct;71(4):1635-42. PMID: 9751197

Research Participants
Copyright © 2005- 2014 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright